Merck's (MRK.US) Keytruda immunotherapy combination has received full FDA approval.

The U.S. FDA today (March 20) announced the full approval of Keytruda (pembrolizumab), a Merck & Co., Inc. (MRK.US) developed heavyweight PD-1 inhibitor, in combination with trastuzumab, fluoropyrimidine, and platinum chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1). Keytruda previously received FDA accelerated approval for this indication in 2021.